ANDA 76062, held by Strides Pharma. Zolpidem Tartrate.
As of Nov 21, 2026, ANDA 76062 (Zolpidem Tartrate), held by Strides Pharma, was first approved by FDA on Apr 23, 2007, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2007 | Original application | Approved |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Mar 7, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 7, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 23, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters